Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033480 | 0.81 | PRCP (0.53) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL29040260 | 0.81 | PRCP (0.53) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL3113641 | 0.81 | CHRNB2 (0.40) | PRCPTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL7433419 | 0.75 | HTR2A (0.42) | PRCPGAATSHRNPSR1HTR2A | |
| SCHEMBL16968352 | 0.75 | PRCP (0.49) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL1319681 | 0.75 | PRCP (0.58) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL2294066 | 0.75 | PRCP (0.58) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL24017043 | 0.74 | PRCP (0.70) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL30368634 | 0.74 | PRCP (0.70) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL16799768 | 0.74 | PRCP (0.70) | PRCPGAATSHRNPSR1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | claimed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | claimed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | claimed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | claimed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | claimed |
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | SHAPIRO STANLEY S (US) | 2012-02-02 | — | — | US | claimed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | claimed |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | claimed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | claimed |
| JP-4401441-B2 | — | — | 2010-01-20 | — | — | JP | claimed |
| EP-0505680-B1 | Octapeptide or heptapeptide derivatives, a process for preparing them as well as medicaments containing these compounds and the use of them | BIOSIGNAL KUTATO FEJLESZTOE (HU) | 1995-04-26 | — | — | EP | claimed |
| EP-0401676-B1 | Enzyme inhibitors | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-01-11 | — | — | EP | claimed |
| EP-0625983-A1 | HETEROTRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-30 | — | — | EP | claimed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | claimed |
| WO-1993015083-A1 | HETEROTRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | claimed |
| EP-0505680-A1 | Octapeptide or heptapeptide derivatives, a process for preparing them as well as medicaments containing these compounds and the use of them | BIOSIGNAL Kutato-Fejleszto Kft. (HU) | 1992-09-30 | — | — | EP | claimed |
| EP-0476515-A1 | New amino acid derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-25 | — | — | EP | claimed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | claimed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | claimed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | TYR, MC1R, NQO1 | PRCP 191/4885GAA 1943/4885TSHR 3545/4885 |
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | PRCP 3931/4885GAA 4225/4885TSHR 1585/4885 |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | PRCP 2918/4885GAA 3958/4885TSHR 939/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | PRCP 3241/4885GAA 4784/4885TSHR 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.